Navigation Links
Sponges as drugs

Dutch researcher Nicole de Voogd has investigated the possibilities for rearing sea sponges in Indonesia. Some of these sponges contain substances of interest to the pharmaceutical industry. As these are increasingly difficult to obtain, there is growing interest in alternative methods of exploitation, such as rearing sponges.

For her research, De Voogd described three new species of sponges and examined the interactions of four sponge species with possible spatial competitors. She discovered that as soon as certain sponge species grow over corals, the coral develops necrotic tissue. From this she concluded that the sponges concerned produce their bioactive substances to defeat spatial competitors. This is important, as in an environment without spatial competitors, such as in a sponge culture, a lower concentration of the substances of interest to the pharmaceutical industry might be produced.

Sponge culture

The researcher tried to rear 9 of the 151 species of sponge observed but was successful with only 3 species. Although the survival rates of these species were generally very high, the growth rates were very slow and unpredictable. Moreover, the reared sponges produced less of the biologically-active substances than their natural counterparts.

Although Indonesia has a very high diversity of sponge species, and therefore a large number of biologically-active substances with pharmaceutical potential, most of the species occur in relatively low densities compared to species in temperate areas. De Voogd discovered that as a result of this low natural density, surprisingly few Indonesian species are suitable for sea rearing.

Sea rearing

Sedentary marine invertebrates such as sponges, are an important source for a large variety of biologically-active substances. Until more advanced techniques such as chemical synthesis, genetic modification and sponge cell culture are realised, rearing in the sea remains the most reliable and effective method for obtaining the large quantities of sponge biomass, necessary for developing drugs.

However, sea rearing can only be used for the large-scale production of useful substances if it can yield large quantities of the sponge species. Therefore, sea rearing would only seem to be a profitable option if the quantities of the substance needed are small or if the growth can be optimised in combination with other reared organisms.

Nicole de Voogd's research was funded by NWO.


'"/>

Source:Netherlands Organization for Scientific Research


Related biology news :

1. Researchers identify target for cancer drugs
2. MetaChip provides quick, efficient toxicity screening of potential drugs
3. Newly discovered pathway might help in design of cancer drugs
4. UNC launches study of liver injury caused by drugs
5. UCLA study assesses cost-effectiveness of Hepatitis B drugs
6. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
7. FDA approves more generic AIDS drugs
8. Virginia Tech group adds tools to DNA-targeted anti-cancer drugs
9. Scientists discover that three molecules may be developed into new Alzheimers drugs
10. Scientists to mimic nature for newest cancer drugs
11. Bacteria are key to green plastics, drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... commercializing its flagship CytoSorb® blood filter to treat ... around the world, announced that CEO Dr. ... the Source Capital Group,s 2016 Disruptive Growth & ... the company.  Conference Presentation Details: ...
(Date:2/4/2016)... BETHESDA, Md. , Feb. 4, 2016  Spherix ... committed to the fostering and monetization of intellectual property, ... VTech and Uniden in the Northern District of ... are moving forward.  Inter Partes ... the U.S. Patent Office.  The IPR was initiated on ...
Breaking Biology Technology: